TruSight™ Oncology Comprehensive
The first CE-marked IVD kitted solution for comprehensive genomic profiling (CGP) of DNA and RNA variants, plus MSI and TMB, for multiple solid tumor types.
Receive your quote directly from the manufacturer.
TruSight Oncology Comprehensive (EU) is a CE-marked IVD next-generation sequencing (NGS)-based CGP for analyzing > 28 solid tumor types using minimal tissue
- Detect DNA plus RNA variants along with biomarker signatures such as TMB and MSI
- Save time and money by assessing multiple biomarkers in a single test
- Enable targeted therapies and clinical trials with actionable, easy-to-interpret results
TruSight Oncology Comprehensive (EU) is an in vitro diagnostic test that uses targeted next generation sequencing to detect variants in 517 genes using nucleic acids extracted from formalin-fixed, paraffin embedded (FFPE) tumor tissue samples from cancer patients with solid malignant neoplasms using the Illumina NextSeq 550Dx instrument. The test can be used to detect single nucleotide variants, multinucleotide variants, insertions, deletions and gene amplifications from DNA, and gene fusions and splice variants from RNA. The test also reports a Tumor Mutational Burden (TMB) score and Microsatellite Instability (MSI) status.
For In Vitro Diagnostic Use
Contact an Illumina representative for regional availability.
Brochures
TruSight Oncology Comprehensive (EU): A new era for better patient outcomes
In this brochure, Illumina highlights TruSight™ Oncology Comprehensive (EU), a next-generation sequencing solution that enables institutions to offer in-house comprehensive genomic profiling for cancer, emphasizing its clinically relevant biomarker coverage, alignment with drug labels and European Society for Medical Oncology (ESMO) recommendations. By implementing the test in-house, labs gain control over sample logistics and data management, improve sample QC and biomarker-informed case rates, and strengthen their role as precision medicine providers.
TruSight Oncology Comprehensive (EU)
In this data sheet, Illumina presents TruSight™ Oncology Comprehensive (EU), a CE-marked, IVD, kitted solution for next-generation sequencing based comprehensive genomic profiling in cancer diagnostics. Illumina highlights its integrated workflow for DNA and RNA analysis of 517 clinically relevant cancer-associated genes, including library preparation, sequencing on the NextSeq™ 550Dx System, and automated variant calling and report generation. This solution enables labs to deliver timely, reliable, and clinically actionable results with streamlined implementation, reduced sample requirements, and minimized verification effort compared to laboratory-developed tests.
Clinical Diagnostics Scientists’ Choice Awards winners announced at ADLM 2025
Roche Diagnostics, Illumina, and Siemens Healthineers among those recognized
